Inhibition of mutated, activated BRAF in metastatic melanoma.
BACKGROUND
The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.


METHODS
We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the maximum dose that could be administered without adverse effects (the recommended phase 2 dose). Patients received PLX4032 twice daily until they had disease progression. Pharmacokinetic analysis and tumor-response assessments were conducted in all patients. In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.


RESULTS
A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase. The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia. In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response. Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response. The estimated median progression-free survival among all patients was more than 7 months.


CONCLUSIONS
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)
Flaherty
Keith T
KT
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA. kflaherty@partners.org
Puzanov
Igor
I
Kim
Kevin B
KB
Ribas
Antoni
A
McArthur
Grant A
GA
Sosman
Jeffrey A
JA
O'Dwyer
Peter J
PJ
Lee
Richard J
RJ
Grippo
Joseph F
JF
Nolop
Keith
K
Chapman
Paul B
PB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D008875:Middle Aged; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome; D000077484:Vemurafenib; D055815:Young Adult
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
Br J Cancer. 2006 Sep 4;95(5):581-6
16880785
J Clin Oncol. 2009 May 1;27(13):2129-36
19289622
Cancer Res. 2003 Apr 1;63(7):1454-7
12670889
J Clin Oncol. 2009 Jun 10;27(17):2823-30
19349552
Nature. 2002 Jun 27;417(6892):949-54
12068308
Nature. 2010 Mar 18;464(7287):427-30
20179705
Nature. 2010 Mar 18;464(7287):431-5
20130576
J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
12644542
N Engl J Med. 2005 Nov 17;353(20):2135-47
16291983
Cancer Res. 2002 Nov 15;62(22):6451-5
12438234
Cancer Treat Rep. 1976 Feb;60(2):165-76
769969
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
Nat Rev Drug Discov. 2004 Sep;3(9):749-61
15340385
J Clin Oncol. 1999 Jul;17(7):2105-16
10561265
J Natl Cancer Inst. 2003 Apr 16;95(8):625-7
12697856
J Clin Oncol. 2008 May 1;26(13):2178-85
18445842
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
14602780
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Int J Cancer. 2006 Oct 15;119(8):1858-62
16721785
Cancer Res. 2003 Sep 1;63(17):5209-12
14500346
Gut. 2003 May;52(5):706-12
12692057
J Transl Med. 2010 Apr 20;8:39
20406486
Oncogene. 2003 Dec 11;22(57):9192-6
14668801
J Clin Oncol. 2000 Jan;18(1):158-66
10623706
J Clin Oncol. 2006 Oct 10;24(29):4738-45
16966688
Oncogene. 2003 Sep 25;22(41):6455-7
14508525
Cell. 2010 Jan 22;140(2):209-21
20141835
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6
18287029